B Cell Lymphoma
News
Transplant strategy not viable for aggressive B-NHL
Transplant with radioimmunotherapy (RIT)-based conditioning is a viable treatment option for patients with indolent—but not aggressive—B-cell non-...
News
JAK inhibition linked to B-cell lymphoma
New research indicates that JAK inhibitors may increase the risk of lymphoma in patients with myelofibrosis (MF). The patients studied had a 15-...
Conference Coverage
‘Very encouraging’ results in BPDCN
STOCKHOLM—Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell...
News
CHMP recommends CAR T for ALL, DLBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of tisagenlecleucel (Kymriah®,...
News
CHMP recommends CAR T for DLBCL, PMBCL
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for the chimeric antigen receptor (...
News
European Medicines Agency recommends CAR T-cell approvals
The therapies must be approved by the European Commission before they can be marketed to patients.
News
Bortezomib plus vorinostat shows modest response in MCL
The phase 2 trial looked at the combination in mantle cell lymphoma and diffuse large B-cell lymphoma patients.
Conference Coverage
Doc reports favorable results from trial on hold
STOCKHOLM—Interim trial results suggest the EZH2 inhibitor tazemetostat can produce durable responses in patients with relapsed or refractory...
News
CPI-613 receives orphan designation for BL
The US Food and Drug Administration (FDA) has granted orphan drug designation to CPI-613 for the treatment of Burkitt lymphoma (BL). CPI-613 is a...
Conference Coverage
CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort
CHICAGO – Could liso-cel be the next CAR T-cell therapy to compete in DLBCL?